EUVIMEDEUVIMED entdecken
Open Access · CC0

Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters

Xueqiao Liu, Hong-Su Park, Yumiko Matsuoka, Celia Santos, Lijuan Yang, Cindy Luongo, Ian N Moore, Reed F Johnson, Nicole L Garza, Peng Zhang, Paolo Lusso, Sonja M Best und 2 weitere

PLOS Pathogens · 2023

DOI: 10.1371/journal.ppat.1011057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Xueqiao Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesd…. Hauptthemen laut MEDLINE: COVID-19, Paramyxoviridae Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Intramural NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pediatric live-attenuated bovine/human parainfluenza virus type 3 (B/HPIV3)-vectored vaccine expressing the prefusion-stabilized SARS-CoV-2 spike (S) protein (B/HPIV3/S-2P) was previously evaluated in vitro and in hamsters. To improve its immunogenicity, we generated B/HPIV3/S-6P, expressing S further stabilized with 6 proline mutations (S-6P). Intranasal immunization of hamsters with B/HPIV3/S-6P reproducibly elicited significantly higher serum anti-S IgA/IgG titers than B/HPIV3/S-2P; hamster sera efficiently neutralized variants of concern (VoCs), including Omicron variants. B/HPIV3/S-2P and B/HPIV3/S-6P immunization protected hamsters against weight loss and lung inflammation following SARS-CoV-2 challenge with the vaccine-matched strain WA1/2020 or VoCs B.1.1.7/Alpha or B.1.351/Beta and induced near-sterilizing immunity. Three weeks post-challenge, B/HPIV3/S-2P- and B/HPIV3/S-6P-immunized hamsters exhibited a robust anamnestic serum antibody response with increased neutralizing potency to VoCs, including Omicron sublineages. B/HPIV3/S-6P primed for stronger anamnestic antibody responses after challenge with WA1/2020 than B/HPIV3/S-2P. B/HPIV3/S-6P will be evaluated as an intranasal vaccine to protect infants against both HPIV3 and SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Paramyxoviridae InfectionsCricetinaeHumansAnimalsCattleChildSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, ViralViral Fusion ProteinsVaccines, AttenuatedParainfluenza Virus 3, HumanAntibodies, Neutralizing

Substanzen

spike protein, SARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, ViralViral Fusion ProteinsVaccines, AttenuatedAntibodies, Neutralizing

Autor:innen und Institutionen

  • RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Infectious Disease and Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • SARS-CoV-2 Virology Core, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.

ORCID-Profile: Cyril Le Nouën

Förderung

  • Intramural NIH HHS
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Liu, X., Park, H. S., Matsuoka, Y., Santos, C., Yang, L., Luongo, C., Moore, I. N., Johnson, R. F., Garza, N. L., Zhang, P., Lusso, P., Best, S. M., Buchholz, U. J., & Le Nouën, C. (2023). Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011057

Vancouver

Liu X, Park HS, Matsuoka Y, Santos C, Yang L, Luongo C, et al. Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011057

BibTeX
@article{Liu2023,
  author = {Liu, Xueqiao and Park, Hong-Su and Matsuoka, Yumiko and Santos, Celia and Yang, Lijuan and Luongo, Cindy and Moore, Ian N and Johnson, Reed F and Garza, Nicole L and Zhang, Peng and Lusso, Paolo and Best, Sonja M and Buchholz, Ursula J and Le Nouën, Cyril},
  title = {Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters},
  journal = {PLOS Pathogens},
  year = {2023},
  doi = {10.1371/journal.ppat.1011057}
}
Kostenlos starten →